Lisata Therapeutics, Inc. and Kuva Labs Inc. entered into an Amendment to Binding Term Sheet on February 27, 2026, extending the Term Sheet's expiration date from February 28, 2026, to March 7, 2026. The Term Sheet contemplates negotiation of a Purchase Agreement for Kuva to acquire all outstanding shares of Lisata via tender offer and short-form merger.
Key takeaways
Binding Term Sheet dated January 20, 2026, between Lisata Therapeutics, Inc. and Kuva Labs Inc.
Term Sheet Amendment dated February 27, 2026, extends expiration to March 7, 2026
Kuva to commence tender offer for all outstanding common stock of Lisata on fully-diluted basis
Post-tender offer, Kuva to complete short-form merger under Section 251(h) of Delaware General Corporation Law
Tender offer not yet commenced; materials to be filed on Schedule TO and Schedule 14D-9
Exhibit 10.1: Amendment to Binding Term Sheet filed